Bukwang initiates dosing of JM-010 in Europe phase 2 study
[January 10, 2020]
Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe. In late 2019, Bukwang successfully initiated phase 2 clinical study of JM-010, which is being developed to treat dyskinesia in Parkinson’s disease, in a number of European countries, and the progress is cruising as company expected. JM-010 is a new drug candidate developed by Bukwang’s subsidiary, Contera...
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
[November 13, 2019]
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseases including Alzheimer’s...
Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years. Since Bukwang was listed in the Korea Stock Exchange in 1988, Bukwang is proud to have kept a health...